Biomerieux SA
PAR:BIM

Watchlist Manager
Biomerieux SA Logo
Biomerieux SA
PAR:BIM
Watchlist
Price: 99.55 EUR 0.86%
Market Cap: 11.7B EUR
Have any thoughts about
Biomerieux SA?
Write Note

Biomerieux SA
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biomerieux SA
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Biomerieux SA
PAR:BIM
Accounts Receivables
€695.1m
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
6%
Edap Tms SA
NASDAQ:EDAP
Accounts Receivables
€19.2m
CAGR 3-Years
19%
CAGR 5-Years
10%
CAGR 10-Years
9%
Carmat SA
PAR:ALCAR
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biosynex SA
PAR:ALBIO
Accounts Receivables
€10.2m
CAGR 3-Years
-9%
CAGR 5-Years
21%
CAGR 10-Years
24%
Visiomed Group SA
PAR:ALVMG
Accounts Receivables
€1.2m
CAGR 3-Years
67%
CAGR 5-Years
4%
CAGR 10-Years
-1%
Amplitude Surgical SA
PAR:AMPLI
Accounts Receivables
€14.7m
CAGR 3-Years
12%
CAGR 5-Years
3%
CAGR 10-Years
N/A
No Stocks Found

Biomerieux SA
Glance View

Market Cap
11.7B EUR
Industry
Health Care

Show Overview: BioMérieux SA: Pioneering Diagnostics for a Healthier World BioMérieux SA, a French multinational founded in 1963, stands at the forefront of the global diagnostics industry, driving innovation in infectious disease testing and food safety. With a mission to improve public health through advanced diagnostic solutions, the company has developed a robust portfolio of products that include molecular biology, microbiology, and immunoassays. Its cutting-edge technologies empower healthcare professionals to detect pathogens with speed and accuracy, making a direct impact on patient outcomes and aiding in the prevention of disease outbreaks. By continuously investing in research and development, BioMérieux not only maintains its competitive edge but also expands its reach in emerging markets, balancing its operations with a strong commitment to sustainability and social responsibility. As health crises grow more complex and interconnected, BioMérieux's efforts to enhance diagnostic capacity have never been more critical. The company's recent forays into automation and artificial intelligence signal a shift toward more integrated and efficient testing systems, equipping laboratories and healthcare providers worldwide with the tools necessary to meet rising healthcare demands. Investors can see the potential for substantial returns not only through BioMérieux's innovative product offerings but also through its strategic partnerships and global expansion initiatives. With a solid financial foundation and a vision anchored in improving patient care, BioMérieux represents a compelling opportunity for investors looking to align with a company dedicated to making a meaningful difference in the health of communities across the globe.

BIM Intrinsic Value
104.34 EUR
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Biomerieux SA's Accounts Receivables?
Accounts Receivables
695.1m EUR

Based on the financial report for Jun 30, 2024, Biomerieux SA's Accounts Receivables amounts to 695.1m EUR.

What is Biomerieux SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
6%

Over the last year, the Accounts Receivables growth was 6%. The average annual Accounts Receivables growth rates for Biomerieux SA have been 9% over the past three years , 7% over the past five years , and 6% over the past ten years .

Back to Top